Cipla’s Goa facility receives VAI classification from US FDA after April inspection, indicating no regulatory or enforcement action is required.
SENSEX 73,832.55
NIFTY 23,161.60
CRUDEOIL 8,611.00
GOLD 147,240.00
SILVER 233,661.00
Cipla shares soared 3.7% on Friday despite a 39% decline in first-quarter PAT, with the stock trading at ₹1,426.40 on the NSE.
Pharma exporters raise concerns over customs delays at Nhava Sheva Port; Pharmexcil to address issues with JNCH officials.
Pursuant to review of a complaint from an investor, SEBI has observed a procedural delay in verifying the eligibility of investor…
Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from…
FSSAI targets multiple brands for misleading claims and labeling violations, enforcing compliance with food safety regulations.
Partnership to ensure a reliable supply of a key industrial input while promoting greater resource optimisation, operational…
